Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 3123

Boehringer Ingelheim, Lilly Announce Academic Collaboration With University Of Oxford

Boehringer Ingelheim and Eli Lilly announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance on the progression of kidney disease and the occurrence of cardiovascular death, in adults with established chronic kidney disease with and without diabetes.

Read More »

Sirenas, Bristol-Myers Squibb enter collaboration

Bristol-Myers Squibb will deploy Sirenas’ drug discovery platform against certain undisclosed challenging therapeutic targets to identify potential drug candidates.

Read More »

Gates backs Central America malaria elimination plan with $31 million

Philanthropist Bill Gates’ fund is aimed at wiping out the disease in seven of the region’s countries and the Dominican Republic.

Read More »

Top 20 Life Science Startups to Watch in 2018

BioSpace present its NextGen Bio “Class of 2018,” a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.

Read More »

Array BioPharma Spins Off Heart Drug R&D Into New Subsidiary Yarra Therapeutics

Array BioPharma spun off some intellectual property and equipment into a new company, Yarra Therapeutics.

Read More »

Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy

Biogen and Ionis Pharmaceuticals announced that they entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy (SMA).

Read More »

Zymeworks, Janssen Biotech Ink R&D Deal

Shares of Zymeworks shot up more than 33 percent after the company announced a licensing deal with Janssen Biotech to develop six bispecific antibodies.

Read More »

Boehringer, MiNA Therapeutics Forge NASH Deal

Boehringer Ingelheim struck a deal targeting liver disease with MiNA Therapeutics.

Read More »

MacroGenics, Incyte Score $900M R&D Deal

Icyte Corporation struck a deal worth up to $900 million with Maryland-based MacroGenics Inc. for that company’s investigational PD-1 inhibitor.

Read More »

Visterra Inks $1B Deal With Vir Biotechnology

Two weeks after securing more than $46 million in financing, Visterra struck a deal worth up to $1 billion with startup Vir Biotechnology.

Read More »

Lilly, CureVac Strike $1.8B mRNA R&D Pact

Eli Lilly signed an R&D collaboration deal with CureVac that could total up to $1.8 billion to develop and commercialize up to five possible cancer vaccines.

Read More »

Warp Drive Bio Scores $387M R&D Pact With Roche

Through a strategic collaboration deal with Roche, Warp Drive Bio will use its Genome Mining Platform to investigate potential antibiotics for drug-resistant Gram-negative bacteria.

Read More »

KalVista Reaches $760 Million Deal With Merck

KalVista Pharmaceuticals Inc. inked a collaboration deal with Merck & Co. for potential therapeutic treatments for diabetic macular edema.

Read More »

Takeda Forges Alliance with Stanford University

Takeda Pharmaceutical announced a collaboration to help transform novel Stanford University research into next-generation treatments for diseases.

Read More »

Celgene Revamps Pact With Sutro Biopharma

Sutro Biopharma and Celgene modified their 2014 immuno-oncology collaboration revolving around four programs that are in preclinical development.

Read More »

AstraZeneca, Merck Seal $8.5 Billion R&D Cancer Deal

Two pharma giants are combining forces to take on multiple cancers in a deal worth up to $8.5 billion.

Read More »

Lilly and Nektar Therapeutics Announce Alliance

Eli Lilly and Nektar Therapeutics announced a strategic collaboration to co-develop NKTR-358, a novel immunological therapy discovered by Nektar.

Read More »

Corning, Merck & Co. and Pfizer to Invest $4 Billion and Create 4,000 New Jobs in the U.S.

Corning announced at President Trump’s “Made in America” event that the company planned to create 1,000 new high-tech jobs in the U.S.

Read More »

Novo Nordisk and Glooko advance their digital health collaboration with launch of unique integrated app for improved diabetes management

Novo Nordisk and Glooko announced that the new Cornerstones4Care Powered by Glooko app (C4C app) is now available to help people more effectively manage their diabetes.

Read More »

Genentech returns drug rights to NewLink

Genentech is returning the rights to NewLink Genetics’ IDO inhibitor GDC-0919 (navoximod). However, the overall research collaboration the two companies have to identify next-generation IDO/TDO (tryptophan 2,3-dioxygenase) inhibitors will continue.

Read More »

Page 1 of 3123

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation